An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01665911 |
|
Recruitment Status :
Completed
First Posted : August 16, 2012
Results First Posted : August 21, 2014
Last Update Posted : February 23, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Caries | Drug: 1.5 mg Sodium Fluoride in 100 ml milk Drug: 1.5 mg sodium fluoride in 200 ml milk Drug: 3 mg sodium fluoride in 100 ml milk Drug: 3 mg sodium fluoride in 200 ml milk Other: Non-fluoridated milk, 200 ml | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 28 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Double (Investigator, Outcomes Assessor) |
| Official Title: | An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy |
| Study Start Date : | August 2012 |
| Actual Primary Completion Date : | April 2013 |
| Actual Study Completion Date : | June 2013 |
| Arm | Intervention/treatment |
|---|---|
|
Arm 1
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Drug: 1.5 mg Sodium Fluoride in 100 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 1.5 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 100 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Other: Non-fluoridated milk, 200 ml Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Name: Kroger Nonfat Dry Milk |
|
Arm 2
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Drug: 1.5 mg Sodium Fluoride in 100 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 1.5 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 100 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Other: Non-fluoridated milk, 200 ml Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Name: Kroger Nonfat Dry Milk |
|
Arm 3
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Drug: 1.5 mg Sodium Fluoride in 100 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 1.5 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 100 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Other: Non-fluoridated milk, 200 ml Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Name: Kroger Nonfat Dry Milk |
|
Arm 4
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Drug: 1.5 mg Sodium Fluoride in 100 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 1.5 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 100 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Other: Non-fluoridated milk, 200 ml Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Name: Kroger Nonfat Dry Milk |
|
Active Comparator: Arm 5
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Drug: 1.5 mg Sodium Fluoride in 100 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 1.5 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 100 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Names:
Drug: 3 mg sodium fluoride in 200 ml milk Each subject will use this product during one of the five treatment periods in the crossover study design
Other Names:
Other: Non-fluoridated milk, 200 ml Each subject will use this product during one of the five treatment periods in the crossover study design.
Other Name: Kroger Nonfat Dry Milk |
- % Surface Microhardness (SMH) Recovery Score Per Each of Five Arms [ Time Frame: Three Weeks per each of five arms ]
- surface microhardness recovery is a measure of caries lesion remineralization and is calculated using the following equation:
- SMHr=(D1-R)/(D1-B)×100 B = indentation length of sound enamel specimen at baseline D1 = indentation length after first in vitro demineralization R = indentation length after intra-oral exposure (rehardening).
- % Acid Resistance Score Per Each of Five Arms [ Time Frame: Three Weeks per each of five arms ]% Acid Resistance is a measure of acid resistance of the remineralized caries lesion which is calculated as (D1-D2)/(D1-B)*100%, where B is the indentation length of sound enamel specimen at baseline, D1 is an indentation length after first in vitro demineralization, D2 is an indentation length after second in vitro demineralization.
- Enamel Fluoride Uptake Per Each of Five Arms [ Time Frame: Three Weeks per each of five arms ]Enamel fluoride uptake is a measure of fluoridation of a caries lesion
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
- be between 18 and 80 years old and in general good health;
- willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
- wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
- be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
- be in good dental health with no active caries or periodontal disease;
- agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
- Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening
Exclusion Criteria:
be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.
- have any medical condition that could be expected to interfere with the subject's safety during the study period;
- demonstrate an inability to comply with study procedures;
- have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning* or previous use of the weight loss medications Fen Phen® or Redux®. (*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
- be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
- be lactose intolerant or have known allergy or intolerance to milk or milk products
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01665911
| United States, Indiana | |
| Oral Health Research Institute, Indiana University School of Dentistry | |
| Indianapolis, Indiana, United States, 46202 | |
| Principal Investigator: | Frank Lippert, PhD | Indiana University | |
| Principal Investigator: | Domenick Zero, DDS, MS | Indiana University |
| Responsible Party: | Frank Lippert, Assistant Research Professor, Indiana University |
| ClinicalTrials.gov Identifier: | NCT01665911 |
| Other Study ID Numbers: |
12-I-086 |
| First Posted: | August 16, 2012 Key Record Dates |
| Results First Posted: | August 21, 2014 |
| Last Update Posted: | February 23, 2015 |
| Last Verified: | February 2015 |
|
Caries |
|
Listerine Fluorides Sodium Fluoride Cariostatic Agents |
Protective Agents Physiological Effects of Drugs Anti-Infective Agents, Local Anti-Infective Agents |

